References
- Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341(8): 556–62
- Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (5 Suppl 1): S35–46
- McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339(21): 1485–92
- Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon al- pha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352(9138): 1426–32
- Lau DT, Kleiner DE, Ghany MG, et al. 10-Year follow-up after interferon- alpha therapy for chronic hepatitis C. Hepatology 1998;28(4): 1121–7
- Poynard T, McHutchison J, Goodman Z, et al. Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000;31(1): 211–8
- Strader DB. Understudied populations with hepatitis C. Hepatology 2002: 36(5 Suppl 1):S226–36
- Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36(5 Suppl 1):S179–84
- Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology 2002: 36(5 Suppl 1):S220–5
- Lau JY, Tam RC, Liang TJ, et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35(5): 1002–9
- Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000:68(5): 556–67
- Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001: 358(9286):958–65
- Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13): 975–82
- Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40KD) in combination with ribavirin: efficacy and safety results from a phase III randomized, double-blind multicenter study examining the effect of duration of treatment and RBV dose. (Abstr) J Hepatol 2002; 36(Suppl 1):3
- McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123(4): 1061–9
- Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36(5 Suppl 1): S145–51
- Jacobson IM, Russo MW, Brown RS Jr, et al. Pegylated interferon alfa- 2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonre-sponders to interferon monotherapy or combination therapy and in combination therapy relapsers. (Abstr) Gastroenterology 2002; 36(5 Suppl 1):A626 Stan
- Shiffman ML. Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. (Abstr) Hepatology 2002; 36(4 Pt 2):295A